Suppr超能文献

主动监测与肾切除术治疗 T1a 小肾癌的匹配分析。

A Matched Analysis of Active Surveillance Versus Nephrectomy for T1a Small Renal Masses.

机构信息

Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada.

Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre-University Health Network, Toronto, Canada.

出版信息

Eur Urol Oncol. 2023 Oct;6(5):535-539. doi: 10.1016/j.euo.2023.01.008. Epub 2023 Feb 4.

Abstract

While patients with a small renal mass (SRM) on active surveillance (AS) experience excellent metastasis-free survival (MFS) and cancer-specific survival (CSS), differences in overall survival (OS) observed may be explained by selection of older/comorbid patients for AS. Few studies have evaluated AS versus primary intervention in clinically balanced groups. We identified patients aged 55-75 yr with an SRM (≤4 cm, T1a) in our institutional database (2000-2020). Patients from AS and nephrectomy subgroups were matched exactly for age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, biopsy status, and histology. The primary outcomes were OS and an event-free survival (EFS) composite that included OS, CSS, MFS, progression, or systemic therapy, which we tested in Cox proportional-hazards models. We identified 377 patients (205 AS, 172 nephrectomy). The cohort was balanced after matching (n = 110; mean age 64 yr, 77% male, and 75% ECOG score 0). In each arm, 47% were biopsied (predominantly clear-cell histology). The predicted 5-yr OS was 96% for the nephrectomy group and 95% for the AS group (hazard ratio for nephrectomy vs AS [HR] 0.83, 95% confidence interval [CI] 0.13-5.32; p = 0.8), with corresponding 5-yr EFS rates of 93% and 96% (HR 1.88, 95% CI 0.35-10.15; p = 0.5). Among SRM cases well matched for age and overall health status, we observed higher 5-yr OS and EFS rates for AS than previously reported; the rates were not significantly different from those after nephrectomy. The matched characteristics of our population are similar to those for treatment arms in contemporary cohorts and the results support the safety of AS in younger, healthier patients. PATIENT SUMMARY: While it has been shown that active surveillance for small kidney tumors is safe in older and more frail patients, its safety in younger, healthier patients has not been confirmed. We compared outcomes for patients aged 55-75 yr who were managed with surgery or active surveillance, and were similar in age and overall health. The probability of death after 5 years was low overall and not significantly different between the groups, suggesting that active surveillance is safe in routine clinical practice.

摘要

虽然接受主动监测 (AS) 的小肾肿瘤 (SRM) 患者具有出色的无转移生存 (MFS) 和癌症特异性生存 (CSS),但观察到的总体生存 (OS) 差异可能是由于选择了年龄较大/合并症较多的患者进行 AS。很少有研究评估 AS 与临床平衡组中的主要干预措施。我们在机构数据库中确定了年龄在 55-75 岁之间患有 SRM(≤4cm,T1a)的患者(2000-2020 年)。AS 和肾切除术亚组的患者在年龄、性别、东部合作肿瘤学组 (ECOG) 表现状态、活检状态和组织学方面完全匹配。主要结局是 OS 和包括 OS、CSS、MFS、进展或系统治疗的无事件生存 (EFS) 复合结局,我们在 Cox 比例风险模型中对这些结局进行了测试。我们确定了 377 名患者(AS 组 205 名,肾切除术组 172 名)。匹配后,队列平衡(n=110;平均年龄 64 岁,77%为男性,75%的 ECOG 评分为 0)。在每个组中,47%的患者进行了活检(主要为透明细胞组织学)。肾切除术组的预测 5 年 OS 为 96%,AS 组为 95%(肾切除术与 AS 的 HR 0.83,95%CI 0.13-5.32;p=0.8),相应的 5 年 EFS 率分别为 93%和 96%(HR 1.88,95%CI 0.35-10.15;p=0.5)。在年龄和整体健康状况匹配良好的 SRM 病例中,我们观察到 AS 的 5 年 OS 和 EFS 率高于之前的报道;与肾切除术组的结果无显著差异。我们人群的匹配特征与当代队列的治疗组相似,结果支持 AS 在年轻、健康患者中的安全性。患者总结:虽然已经表明,对于年龄较大和身体较弱的患者,主动监测小肾癌是安全的,但在年轻和健康的患者中,其安全性尚未得到证实。我们比较了接受手术或主动监测的 55-75 岁患者的结果,这些患者在年龄和整体健康状况方面相似。5 年后死亡的概率总体较低,两组之间无显著差异,这表明主动监测在常规临床实践中是安全的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验